Syner-G Biopharma Group acquires Impact

By Rachel Arthur

- Last updated on GMT


Related tags regulatory Us

Syner-G BioPharma Group, a provider of Chemistry, Manufacturing, and Controls (CMC) technical, regulatory, and compliance consulting services to the pharmaceutical and biotechnology industry, has acquired Impact Pharmaceutical Services.

The acquisition gives Syner-G Impact's medical writing, regulatory strategy, and regulatory publishing and submission services for biotech and pharma companies; which range from pre-IND through post-marketing of drugs and biologics.

As well as adding Impact’s capabilities, the acquisition gives Southborough, MA headquartered Syner-G a presence in the North Carolina's fast growing biotech hub, Research Triangle Park.

“This acquisition adds medical writing, overall drug development and regulatory strategy, and regulatory publishing and submission services to Syner-G’s capabilities which will allow us to better support our customers as they develop lifesaving and breakthrough therapeutics,”​ stated Prabu Nambiar, Founder and CEO of Syner-G. “The combination brings together two excellent companies with very similar organizational histories, operating philosophies, and corporate cultures.” 

Financial terms of the transaction were not disclosed.   

Related topics Biopharma Culture

Related news